The 2010 CIRCULATE™ Slide Compendium provides practitioners with clinical tools to enable better patient care and helps to increase awareness of the updated clinical guidelines, treatment standards and new therapeutic options, as well as their impact on patient quality of life.

CME Information

Activity Title 2010 CIRCULATE™ Slide Compendium Update
Topic COPD
Target Audience Pulmonologists, primary care physicians (family and internal medicine), physician assistants, nurse practitioners, and respiratory therapists
Accreditation Type CME
Release Date September 2010
Expiration Date September 30, 2011 - CME credit no longer available
Estimated Time to Complete Activity 180 minutes

EDUCATIONAL ACTIVITY OBJECTIVES

Upon completion of the activity, health care providers should be able to:

  • Use established diagnostic criteria to identify patients with COPD at an early stage
  • Incorporate guideline recommendations into the management of patients with COPD
  • Modify the management of patients with COPD to reflect recent clinical results
  • Use a COPD quality improvement tool to improve patient outcomes

CONTENT CREATORS

Donald P. Tashkin, MD
Chairperson
Distinguished Professor of Medicine
Division of Pulmonary and Critical Care Medicine
David Geffen School of Medicine
University of California at Los Angeles
Los Angeles, California

Richard Casaburi, PhD, MD
Associate Chief for Research
Professor of Medicine
Division of Respiratory and Critical Care Physiology and Medicine
Director, Clinical Respiratory Physiology Laboratories
Harbor-UCLA Medical Center
Torrance, California

James F. Donohue, MD
Professor of Medicine
Chief, Division of Pulmonary Diseases and Critical Care Medicine
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Gary T. Ferguson, MD
Director
Pulmonary Research Institute of Southeast Michigan
Livonia, Michigan

Barry J. Make, MD
Professor of Medicine
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado School of Medicine
Aurora, Colorado

Co-Director, COPD Program
Co-Director, COPD Translational Research Initiative
Director, Pulmonary Rehabilitation and Respiratory Care
National Jewish Health
Denver, Colorado
   Fernando J. Martinez, MD, MS
Professor of Internal Medicine
Medical Director, Pulmonary Diagnostic Services
Co-Medical Director, Lung Transplantation
Division of Pulmonary and Critical Care Medicine
University of Michigan Health System
Ann Arbor, Michigan

Stephen I. Rennard, MD
Larson Professor of Medicine, Department of Internal Medicine
Courtesy Professor, Department of Pathology and Microbiology
University of Nebraska Medical Center
Omaha, Nebraska

Sanjay Sethi, MD
Professor, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
University at Buffalo, SUNY

Section Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Western New York VA HealthCare System
Buffalo, New York

Robert A. Wise, MD
Professor of Medicine with Joint Appointment in Environmental Health Sciences
Johns Hopkins Institutions

Director, Pulmonary Function Laboratory
Johns Hopkins Bayview Medical Center
Baltimore, Maryland

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity. (follow the link at the conclusion of the CME information)
  4. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Your CME/CE certificate will be emailed to you.

      6. CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

SPONSOR

This activity is sponsored by The France Foundation.

TARGET AUDIENCE

This educational activity is designed for pulmonologists, primary care physicians (family and internal medicine), physician assistants, nurse practitioners, and respiratory therapists.

STATEMENT OF NEED

COPD is preventable and treatable but not usually reversible. Smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy remain the three main approaches toward modifying the course of COPD. There are multiple guidelines that have been published and updated for the management of COPD. Primary care and pulmonary clinicians are most frequently the ones involved in the diagnosis and management of patients with COPD. In addition to the under diagnosis of COPD, and despite the clinical guidelines, there are many patients that remain undertreated and/or inappropriately treated for their COPD.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME-accredited provider.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

DISCLOSURE

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty have indicated that they have relationships with industry to disclose relative to the content of this CME activity:

  • Dr. Tashkin has received grants/research support from AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Novartis, Osiris, Pfizer, and Schering-Plough. He has served as consultant for AstraZeneca, Boehringer Ingelheim, Pfizer, and Schering-Plough. Dr. Tashkin has received honoraria from AstraZeneca, Boehringer Ingelheim, and Pfizer.
     
  • Dr. Casaburi has received grants/research support from AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Novartis, Osiris, and Roche. He has served as a consultant for Almirall, AstraZeneca, Boehringer Ingelheim, Forest, Novartis, and Pfizer. Dr. Casaburi is a stock holder of Inogen. He has received honoraria from AstraZeneca, Boehringer Ingelheim, and Pfizer.
     
  • Dr. Donohue has received grants/research support from Boehringer Ingelheim and GlaxoSmithKline. He has served as consultant for AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Novartis, and Sepracor. Dr. Donohue has received honoraria from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline.
     
  • Dr. Ferguson has received grants/research support from Boehringer Ingelheim, Forest, GlaxoSmithKline, and Novartis. He has served as a consultant for AstraZeneca, Boehringer Ingelheim, and Sepracor. Dr. Ferguson has received honoraria from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline.
     
  • Dr. Make has received grants/research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nabi, Pfizer, and Sepracor. He has served as a consultant for Astellas, AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Johnson and Johnson, Nycomed, Pfizer, Schering-Plough, and Spiration. Dr. Make has received honoraria from Boehringer Ingelheim, GlaxoSmithKline, and Pfizer .
     
  • Dr. Martinez has received has received grant/research support from Actelion, Gilead, GlaxoSmithKline, Johnson & Johnson, and NIH. He has served as a consultant for Actelion, Almirall/Forest, AstraZeneca, Bayer, Boehringer Ingelheim, Elan, Gilead, GlaxoSmithKline, Mpex, Nycomed/Forest, Roche, and Schering-Plough. Dr. Martinez has received honoraria from Almirall/Forest, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MedEd, Nycomed/Forest, NACE, and Potomac.He has received other financial or material support from Novartis (DSMB).
     
  • Dr. Rennard has received grants/research support from AstraZeneca, BioMarck, Centocor, and Novartis. He has served as consultant for Almirall, Aradigm, AstraZeneca, Boehringer Ingelheim, Defined Health, Dey Labs, Eaton Associates, GlaxoSmithKline, MedaCorp, Mpex, Novartis, Nycomed, Otsuka, Pfizer, Pulmatrix, Theravance, United BioSource, Uptake Medical, and Vantage Point. Dr. Rennard has received honoraria from AstraZeneca, Novartis, Network for Continuing Education, Pfizer, and SOMA.
     
  • Dr. Sethi has received grants/research support from AstraZeneca, Bayer, Boehringer Ingelheim, Mpex, and Novartis. He has served as a consultant for AstraZeneca, Bayer, GlaxoSmithKline, Forest, and Mpex. Dr. Sethi has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Pfizer.
     
  • Dr. Wise has received grants/research support from BIPI, GlaxoSmithKline, Merck, and Schering-Plough. He has served as a consultant for AstraZeneca, BIPI, GlaxoSmithKline, MedImmune, Novartis, Pfizer, and Sepracor.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by educational grant from AstraZeneca.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and AstraZeneca assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2010 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.



To access the educational components, please click on one of the following:
© 2010 The France Foundation. All rights reserved.